


## CLAIMS:

1. A compound having the general formula I:



I

wherein

R1, R2, R3, R4, R5, are each independently selected from H, halogen, NO<sub>2</sub>, CN, C<sub>1-6</sub>alkyl, CF<sub>3</sub>, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, OCF<sub>3</sub>, OR18, SR18, OC<sub>1-6</sub>alkyl, OC<sub>2-6</sub>alkylNR18R19, Oaryl, Oheteroaryl, Ocycloalkyl, Ocycloheteroalkyl, OC<sub>1-6</sub>alkylaryl, OC<sub>1-6</sub>alkylheteroaryl, OC<sub>1-6</sub>alkylcycloalkyl, OC<sub>1-6</sub>cycloheteroalkyl, CO<sub>2</sub>R18, C<sub>1-6</sub>alkylCO<sub>2</sub>R18, CONR18R19, C<sub>1-6</sub>alkylCONR18R19, NR18R19, C<sub>1-6</sub>alkylNR18R19, NR20C<sub>1-6</sub>alkylNR18R19, C<sub>1-6</sub>alkylNR20C<sub>1-6</sub>alkylNR18R19, NR18COR19, C<sub>1-6</sub>alkylNR18COR19, C<sub>1-6</sub>alkylNR20CONR18R19, NR20CONR18R19, C<sub>1-6</sub>alkylNR18SO<sub>2</sub>R19, NR18SO<sub>2</sub>R19;

R18, R19 are each independently selected from H, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkyl cycloheteroalkyl, aryl, heteroaryl, C<sub>1-4</sub>alkyl aryl, C<sub>1-4</sub> alkyl heteroaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21;

R20, R21 are each independently selected from H, C<sub>1-4</sub>alkyl;

R6 is selected from H, C<sub>1-4</sub>alkyl,

R7 is selected from H, C<sub>1-4</sub>alkyl, SH, CN;

R8 is selected from OR9, NR9R10;

R9, R10 are each independently selected from H, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylCO<sub>2</sub>H, C<sub>1-4</sub> alkyl cycloheteroalkyl, aryl, heteroaryl, C<sub>1-4</sub>alkyl aryl, C<sub>1-4</sub> alkyl heteroaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR11;

5 R11 is selected from H, C<sub>1-4</sub>alkyl.

2. A compound according to claim 1 wherein

R1, R2, R3, R4 and R5 are each independently selected from H, OH, OC<sub>1-4</sub>alkyl, OC<sub>1-4</sub>alkylaryl, C<sub>1-4</sub>alkyl, halogen;


R6 is selected from H, C<sub>1-4</sub>alkyl,

10 R7 is selected from H, C<sub>1-4</sub>alkyl, SH, CN;

R8 is selected from OH, NR9R10;

R9, R10 are each independently selected from H, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylCO<sub>2</sub>H.

3. A compound having the general formula II:



20 II

wherein

R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are each independently selected from H, halogen, NO<sub>2</sub>, CN, C<sub>1-6</sub>alkyl, CF<sub>3</sub>, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, OCF<sub>3</sub>, OR18, SR18, OC<sub>1-6</sub>alkyl, OC<sub>2-6</sub>alkylNR18R19, Oaryl, Oheteroaryl, Ocycloalkyl, Ocycloheteroalkyl, OC<sub>1-6</sub>alkylaryl, OC<sub>1-6</sub>alkylheteroaryl,

25

OC<sub>1-6</sub>alkylcycloalkyl, OC<sub>1-6</sub>cycloheteroalkyl, CO<sub>2</sub>R18, C<sub>1-6</sub>alkylCO<sub>2</sub>R18,  
 CONR18R19, C<sub>1-6</sub>alkylCONR18R19, NR18R19, C<sub>1-6</sub>alkylNR18R19,  
 NR20C<sub>1-6</sub>alkylNR18R19, C<sub>1-6</sub>alkylNR20C<sub>1-6</sub>alkylNR18R19, NR18COR19,  
 C<sub>1-6</sub>alkylNR18COR19, C<sub>1-6</sub>alkylNR20CONR18R19, NR20CONR18R19,  
 C<sub>1-6</sub>alkylNR18SO<sub>2</sub>R19, NR18SO<sub>2</sub>R19;

R18, R19 are each independently selected from H, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkyl  
 cycloheteroalkyl, aryl, heteroaryl, C<sub>1-4</sub>alkyl aryl, C<sub>1-4</sub> alkyl heteroaryl, or may  
 be joined to form an optionally substituted 3-8 membered ring optionally  
 containing an atom selected from O, S, NR21;

R20, R21 are each independently selected from H, C<sub>1-4</sub>alkyl;


R11, R12 are each independently selected from H, C<sub>1-4</sub>alkyl, halogen, OC<sub>1-4</sub>alkyl.

4. A compound according to claim 3 wherein

R1, R2, R3, R4, R5, R6, R7, R8, R10 are each independently selected from H,  
 C<sub>1-4</sub>alkyl, OC<sub>1-4</sub>alkyl, CO<sub>2</sub>H, CN;

R11, R12 are each independently selected from H, C<sub>1-4</sub>alkyl.

5. A compound having the general formula III:



wherein

R1, R2, R3, R4, R5 and R6 are each independently selected from H, halogen, NO<sub>2</sub>, CN, C<sub>1-6</sub>alkyl, CF<sub>3</sub>, aryl, heteroaryl, cylcoalkyl, cycloheteroalkyl, OCF<sub>3</sub>, OR18, SR18, OC<sub>1-6</sub>alkyl, OC<sub>2-6</sub>alkylNR18R19, Oaryl, Oheteroaryl, Ocycloalkyl, Ocycloheteroalkyl, OC<sub>1-6</sub>alkylaryl, OC<sub>1-6</sub>alkylheteroaryl, OC<sub>1-6</sub>alkylcycloalkyl, OC<sub>1-6</sub>cycloheteroalkyl, CO<sub>2</sub>R18, C<sub>1-6</sub>alkylCO<sub>2</sub>R18, CONR18R19, C<sub>1-6</sub>alkylCONR18R19, NR18R19, C<sub>1-6</sub>alkylNR18R19, NR20C<sub>1-6</sub>alkylNR18R19, C<sub>1-6</sub>alkylNR20C<sub>1-6</sub>alkylNR18R19, NR18COR19, C<sub>1-6</sub>alkylNR18COR19, C<sub>1-6</sub>alkylNR20CONR18R19, NR20CONR18R19, C<sub>1-6</sub>alkylNR18SO<sub>2</sub>R19, NR18SO<sub>2</sub>R19;

R18, R19 are each independently selected from H, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkyl cycloheteroalkyl, aryl, heteroaryl, C<sub>1-4</sub>alkyl aryl, C<sub>1-4</sub> alkyl heteroaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21;

R20, R21 are each independently selected from H, C<sub>1-4</sub>alkyl;


R7 is selected from H, C<sub>1-6</sub>alkyl, CF<sub>3</sub>, aryl, heteroaryl, cylcoalkyl, cycloheteroalkyl, CO<sub>2</sub>R18, C<sub>1-4</sub>alkylCO<sub>2</sub>R18, CONR18R19, C<sub>1-4</sub>alkylCONR18R19, NR18R19, C<sub>1-6</sub>alkylNR18R19, NR20C<sub>1-4</sub>alkylNR18R19, C<sub>1-6</sub>alkylNR20C<sub>1-4</sub>alkylNR18R19, NR18COR19, C<sub>1-6</sub>alkylNR18COR19, C<sub>1-6</sub>alkylNR20CONR18R19, NR20CONR18R19, C<sub>1-6</sub>alkylNR18SO<sub>2</sub>R19, NR18SO<sub>2</sub>R19 wherein R18, R19 are as defined above.

6. A compound according to claim 5 wherein


R1, R2, R3, R4, R5, and R6 are each independently selected from H, halogen, OH, OC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyl;

R7 is selected from H, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkylCO<sub>2</sub>H.

7. The compound of formula V:



8. A pharmaceutical composition comprising
  - (a) one or more compounds according to any one of claims 1 to 7;
  - (b) a pharmaceutically acceptable diluent.
- 5 9. A method for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment with one or more compounds according to any one of claims 1 to 7 or a composition according to claim 8.
- 10 10. A method according to claim 10 wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.
11. A method for obtaining a compound which modulates Fc receptor activity, the method comprising:
  - (a) providing or designing one or more compounds having structural characteristics to fit in the groove of the FcγRIIa structure; and
  - 15 (b) screening the one or more compounds for modulating activity on the Fc receptor.
12. A method according to claim 11 wherein step (a) comprises functionalising the one or more compounds with one or more substituent groups.
- 13 13. A method according to claim 11 or claim 12 wherein the compounds are screened  
20 by a FcγRIIa dependent platelet activation assay and/or aggregation assay where platelets are activated using heat aggregated human immunoglobulin G as an immune complex.
13. A compound which modulates Fc receptor activity obtained by the method of any one of claims 11 to 13.
- 25 14. A method for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment with a compound having the general formula IV:



IV

wherein

R1, R2, R3, R4, R5 and R6 re each independently selected from H, halogen, NO<sub>2</sub>, CN, C<sub>1-6</sub>alkyl, CF<sub>3</sub>, aryl, heteroaryl, cylcoalkyl, cycloheteroalkyl, OCF<sub>3</sub>, OR18, SR18, OC<sub>1-6</sub>alkyl, OC<sub>2-6</sub>alkylNR18R19, Oaryl, Oheteroaryl, Ocycloalkyl, Ocycloheteroalkyl, OC<sub>1-6</sub>alkylaryl, OC<sub>1-6</sub>alkylheteroaryl, OC<sub>1-6</sub>alkylcycloalkyl, OC<sub>1-6</sub>cycloheteroalkyl, CO<sub>2</sub>R18, C<sub>1-6</sub>alkylCO<sub>2</sub>R18, CONR18R19, C<sub>1-6</sub>alkylCONR18R19, NR18R19, C<sub>1-6</sub>alkylNR18R19, NR20C<sub>1-6</sub>alkylNR18R19, C<sub>1-6</sub>alkylNR20C<sub>1-6</sub>alkylNR18R19, NR18COR19, C<sub>1-6</sub>alkylNR18COR19, C<sub>1-6</sub>alkylNR20CONR18R19, NR20CONR18R19, C<sub>1-6</sub>alkylNR18SO<sub>2</sub>R19, NR18SO<sub>2</sub>R19;

R18, R19 are each independently selected from H, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkyl cycloheteroalkyl, aryl, heteroaryl, C<sub>1-4</sub>alkyl aryl, C<sub>1-4</sub> alkyl heteroaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21;

R20, R21 are each independently selected from H, C<sub>1-4</sub>alkyl.

15. A method according to claim 14 wherein

R1, R2, R3, R4 are each independently selected from H, halogen, NO<sub>2</sub>, OC<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkyl

R5 is selected from H, Cl, OC<sub>1-4</sub>alkyl, OC<sub>1-4</sub>alkylaryl, O C<sub>3-6</sub>cycloalkyl;

R6 is selected from CO<sub>2</sub>H, CONR<sub>7</sub>R<sub>8</sub>;

R7, R8 are each independently selected from H, 5-tetrazole.